Search PubMed⌕ Search

Biomedical subjects

E C Huskisson

Publications and source records attributed to E C Huskisson.

194 records · Page 11Linked to original sources
PubMed1970

Glucose-6-phosphate dehydrogenase deficiency and chronic haemolysis in an English family.

Three male members of an English family with chronic haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency are reported. The disease was symptomless in one adult, but crises, caused either by increased haemolysis or failure of marrow compensation, occurred in two children. They were typically precipitated by trivial infection. Two normal female members of the family were obligatory heterozygotes. A hitherto undescribed ;slow' variant of the enzyme was identified electrophoretically.

Anemia, Hemolytic↗
PubMed1968

Gastric ulceration occurring during indomethacin therapy.

Dyspeptic symptoms, gastrointestinal bleeding, or the development of anaemia without dyspepsia in patients treated with indomethacin may be manifestations of peptic ulceration. Such manifestations occur with suppositories as well as with capsules. The ulcers in the present series tended to be prepyloric, and often aroused the suspicion of malignancy. Symptoms were promptly relieved and radiological healing occurred rapidly after withdrawal of the drug.

Adult↗
PubMedDate not supplied

Measurement of pain.

Explore the source record for details and available documents.

Arthritis↗
PubMedDate not supplied

Other penicillamine-like drugs.

Drugs like penicillamine act slowly, benefit extraarticular features of the disease as well as the joints, reduce erythrocyte sedimentation rate and rheumatoid factor titer and may slow the progression of radiographic changes and alter the outcome of the disease. Their action is to some extent disease-dependent. The 1st choice of drugs of this type is now penicillamine. It compares favourably with other drugs of the same type including gold, azathioprine and levamisole. A number of compounds in the development stage offer potential advantages over currently available drugs of this class. A compound which was safe enough to be recommended for widespread use would take over the role of first-line treatment of rheumatoid arthritis.

Anti-Inflammatory Agents↗
PubMedDate not supplied

The problems of studying disease-remittive agents in RA.

Problems in trials of disease-remittive agents include the slow action and late side effects of these compounds, the lack of immediate benefit to the patient, their characteristic and sometimes dangerous side effects, variability of response, natural fluctuation of the disease, and uncertain definition of drug types. To overcome these problems, trials must be of long duration with large numbers of patients whose characteristics are clearly defined. The 2/3 blind technique overcomes the problem of side effects. Measurements must include aspects of the disease state as well as its articular manifestations. Criteria for the identification of disease-remittive agents include effects in animal models of inflammation, time course, disease-dependence, effects on joint disease and extraarticular manifestations, changes in erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), and immunoglobulins, radiological progression, outcome, and perhaps side effects. The time course of the action of auranofin (AF), similar to that of Myochrysine, with its effects on ESR and RF, support the view that AF is a disease-remittive agent.

Arthritis, Rheumatoid↗
PubMedDate not supplied

The side effects of penicillamine therapy in rheumatoid arthritis.

Penicillamine causes lots of problems. It is also a highly effective treatment which is capable of achieving long-term control of rheumatoid arthritis (RA). The physician's approach to the management of side effects is therefore determined by the patient's response as well as by adverse reactions. The severity of the adverse reaction and its natural history will influence the decision about treatment. There are just 3 options in a patient who develops a side effect due to penicillamine. Treatment may be stopped. It may be stopped and reintroduced, usually using a lower dose and cautious increases. Or it may be continued. Skillful management of side effects is an essential part of the treatment of RA with penicillamine. A therapeutic opportunity has been lost when treatment is stopped in a patient whose disease is controlled. The potential for side effects also influences the decision to use penicillamine and the surveillance required for patients receiving it.

Arthritis, Rheumatoid↗